Shares of Poly Medicure Ltd jumped over 6% in Tuesday’s trade, rising Rs 122.40 to Rs 2,364.60, following a sharp rally triggered by escalating US-China trade tensions and renewed investor interest in Indian medical device makers.
The spike comes after the United States imposed tariffs of up to 245% on Chinese imports, with medical equipment such as syringes and needles specifically targeted. This is part of President Trump’s new executive order that cites national security concerns and over-reliance on China for critical healthcare supplies. The White House also cited China’s retaliatory restrictions on rare earth exports and US chip imports, along with concerns over illegal fentanyl exports.
This geopolitical escalation has renewed focus on domestic alternatives—with Poly Medicure, a leading Indian medical device manufacturer, seen as a potential beneficiary.
Earlier, the company had guided for a 20% revenue growth trajectory over the next three years, citing rising exports and support from the Production-Linked Incentive (PLI) scheme. Managing Director Himanshu Baid had noted that India’s medical device exports have doubled from $2 billion to $4 billion in three years, while import growth is now slowing due to regulatory changes and growing self-reliance.
India has now issued over 3,000 medical device manufacturing licenses, further reinforcing the potential for companies like Poly Medicure to scale operations and fill global supply gaps.
As of 12:41 PM, Poly Medicure was trading at ₹2,364.60, up 5.46%, with a market cap of ₹239.90 billion and P/E ratio of 72.81. The stock’s 52-week high is ₹3,357.80, and it remains one of the key plays in India’s rising medtech landscape amidst global trade realignment.
